Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with …

AS Dobs, BJ Goldstein, P Aschner… - Journal of …, 2013 - Wiley Online Library
摘要背景: 2 型糖尿病(T2D) 是一种进展性的疾病, 它通常需要进行联合治疗,
为了改善患者的血糖控制, 需要新型的治疗方法. 本研究评估了持续使用二甲双胍与罗格列酮 …
被引用次数：52 相关文章

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with …

AS Dobs, BJ Goldstein, P Aschner, ES Horton… - 2013 - pubmed.ncbi.nlm.nih.gov
Background New therapeutic approaches are needed to improve glycemic control in
patients with type 2 diabetes (T2D), a progressive disorder that often requires combination …

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with …

AS Dobs, BJ Goldstein, P Aschner… - Journal of …, 2013 - pure.johnshopkins.edu
Background: New therapeutic approaches are needed to improve glycemic control in
patients with type 2 diabetes (T2D), a progressive disorder that often requires combination …

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with …

AS DOBS, BJ GOLDSTEIN, P ASCHNER… - Journal of …, 2013 - search.ebscohost.com
Background: New therapeutic approaches are needed to improve glycemic control in
patients with type 2 diabetes (T2D), a progressive disorder that often requires combination …

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with …

AS Dobs, BJ Goldstein, P Aschner, ES Horton… - Journal of …, 2013 - europepmc.org
Background New therapeutic approaches are needed to improve glycemic control in
patients with type 2 diabetes (T2D), a progressive disorder that often requires combination …